Guggenheim cuts Immunovant stock target to $44, maintains Buy
Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...
H.C. Wainwright maintains Buy on Immunovant, $51 price target
H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...
Mumbai reports first case of Guillain-Barré Syndrome in 64-year-old woman
GBS is a rare condition in which a person's immune system attacks the peripheral nerves, resulting in muscle weakness, loss ...
Tally of nerve disorder GBS cases rise to 180 in Maharashtra, Mumbai reports first case
MUMBAI: The tally of Guillain Barre Syndrome (GBS) cases in Maharashtra has reached 189, while the first GBS-suspected patient from Andheri-East was detect ...
The Carousel3d
The Swimmer and The Snapper: How an Aussie Olympian and Entrepenueur Found True Love
Michael Klim's new love with founder of Almost Real and Snaaps, Michelle Owen, is about moments, memories and the magic of shared adventures.
Guillain-Barre Syndrome: Know About The Symptoms And The Urgent Need For Early Diagnosis
Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...
The Financial Express3d
GBS Outbreak: Tally of rare neurological disorder reaches 180 in Pune; Mumbai reports first case-Check details
Severe cases of Guillain-Barr syndrome (GBS) can result in near-total paralysis. GBS is more common in adults and males, ...
GBS Outbreak In Maharashtra: Mumbai Reports First Case, Pune Tally Rises To 180
The tally of suspected Guillain-Barré syndrome (GBS) cases in the Pune region has reached 180, with the detection of seven ...